BNP/CALL/MODERNA/250/0.1/17.01.25 | Delayed Deutsche Boerse AG 03:20:57 2024-05-23 am EDT | ||
| 0.84 EUR | -2.33% |
|
| Current month | +473.33% | ||
| 1 month | +616.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 0.84 | -2.33% |
| 24-05-22 | 0.86 | +120.51% |
| 24-05-21 | 0.39 | +5.41% |
| 24-05-20 | 0.37 | +48.00% |
| 24-05-17 | 0.25 | -3.85% |
Delayed Quote Deutsche Boerse AG
Last update May 23, 2024 at 03:20 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PE89DE |
| ISIN | DE000PE89DE4 |
| Date issued | 2023-02-16 |
| Strike | 250 $ |
| Maturity | 2025-01-17 (240 Days) |
| Parity | 10 : 1 |
| Emission price | 2.57 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.28 € |
|---|---|
| Lowest since issue | 0.062 € |
| Spread | 0.03 € |
| Spread % | 3.37% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
163.3
USD
Average target price
138.5
USD
Spread / Average Target
-15.19%
- Stock Market
- Warrants
- Warrant
